ABC transporters: unvalidated therapeutic targets in cancer and the CNS - Wikidata - awgldk - TriplyDB

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

http://www.wikidata.org/entity/Q35056738

about

Research Progress on the Role of ABC Transporters in the Drug Resistance Mechanism of Intractable Epilepsy Hedgehog signaling pathway and its targets for treatment in basal cell carcinoma EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors The blood-testis barrier and its implications for male contraception Modification of marine natural product ningalin B and SAR study lead to potent P-glycoprotein inhibitors Incorporation of ABCB1-mediated transport into a physiologically-based pharmacokinetic model of docetaxel in mice.Behavioral effects and central nervous system levels of the broadly available κ-agonist hallucinogen salvinorin A are affected by P-glycoprotein modulation in vivo.Decreased affinity for efflux transporters increases brain penetrance and molecular targeting of a PI3K/mTOR inhibitor in a mouse model of glioblastoma.Utilisation of nanoparticle technology in cancer chemoresistance.The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells.Melanocytes, melanocyte stem cells, and melanoma stem cells.The role of cell density and intratumoral heterogeneity in multidrug resistance.The role of E3 ubiquitin ligase Cbl proteins in β-elemene reversing multi-drug resistance of human gastric adenocarcinoma cells ABCG2 is not able to catalyze glutathione efflux and does not contribute to GSH-dependent collateral sensitivity.Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function.Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy Efflux transporters in the blood-brain interfaces--in vitro and in vivo methods and correlations.Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.CD133 Is Not Suitable Marker for Isolating Melanoma Stem Cells from D10 Cell Line.Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.Can the assessment of ABCB1 gene expression predict its function in vitro?Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein.Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy.Impacts of blood-brain barrier in drug delivery and targeting of brain tumors Structure of the human multidrug transporter ABCG2.Quantitative evaluation of the combination between cytotoxic drug and efflux transporter inhibitors based on a tumour growth inhibition model.The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1.Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor.The Effects of Synthetically Modified Natural Compounds on ABC Transporters

P2860

Q26780520-3A24E56A-A236-492F-9BBC-08F1196E0F99 Q27021460-808421F8-9457-4E31-AC24-D089B9D170F1 Q27318449-54569958-C486-4F9F-8FB2-868B4EC012D1 Q28395237-D1E932C5-258B-48D2-8EB5-2916BF3F8553 Q34411540-5FB2B952-A144-41D7-B047-2350007D6B4C Q34937463-3A72914F-841C-4014-A288-F4A2C3A4F3E7 Q35996706-E0EC8E96-6010-4430-9956-40C5480E2409 Q36107368-114A4328-E69B-408B-AF2B-74E112DC381E Q36421258-46D889B1-D7B8-4E3A-8936-3A9EA11EE399 Q36446501-3E9C0256-B030-442E-A06D-7FEA5F6ED6A3 Q36640682-F9E0A183-5A78-4C90-A7DD-5475A9B7A2B6 Q36663592-3E84E46C-2F7A-42B5-B2B4-4D0D2F9DDA40 Q36913707-B1F8E982-519B-40B8-A534-B13D4875E064 Q37285224-DFFFB4EF-DDD9-490D-BC0B-5C9A85C25299 Q37407621-31C912AB-886F-485D-969A-BE9EE54795CD Q37612789-E89F3CFD-F214-4DF7-928F-EF6C9BDB570D Q37735146-ABCD0549-B7C8-4348-8150-1B357E8B2031 Q37991010-BAB5E930-54F5-45D0-AFE8-1839753BB01E Q38183877-5CD835D7-D22E-4DC8-9EBC-0FB60099E8E8 Q38207943-0CECED83-F61B-4C77-A294-44DC60B82991 Q38546133-8C4BFC15-FDB6-4075-A2F2-C036565B2F15 Q38743568-E756F295-1D3D-4D4A-8EDA-2DBB46BC51D2 Q38780064-C59469B0-380A-4DD2-A2DA-99FE99342328 Q38901400-2B6712B5-845F-4A92-8E14-4C3057E9B0A2 Q38947143-6DF4F116-D32C-466D-BDE3-2127DED30AFE Q39233676-548F4098-D07A-4EE4-A6C8-5CB53935A669 Q40462770-7B013EBE-00DE-4C59-8C84-16333604B50A Q40552620-AD4AF67C-9497-4B23-ACCA-FA949A9C2621 Q41597764-CC3A2658-A696-40FE-8BB0-58B24804CF7A Q43968777-C321D27D-FEC0-4A29-8075-BCF87C37C8CD Q44176745-FF4D3DB2-2CE3-4F04-A2CE-6F663D5D4020 Q50026203-65E20DBF-7B12-4703-9700-A65CBC4F9940 Q55070104-7672B72A-1163-4F84-AD70-48D10BB11CEF Q58791987-066DB5EF-EECD-471D-8A19-FAC1380C288F

P2860

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

http://www.wikidata.org/entity/Q35056738

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@ast

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@en

type

label

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@ast

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@en

prefLabel

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@ast

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@en

P1433

Q35056738-8A000DBE-5CBB-4458-92DF-CAE5098BB7F2

P1476

Q35056738-9FD64E1A-73BC-489B-885F-6EDBD5F514E3

P2093

Q35056738-C2789852-A281-473E-9336-06597BD5D14A

Q35056738-D2A72E57-08F4-4BA7-91DB-9C50C1EF6507

Q35056738-D8B0AEFE-34F7-4E3A-8433-278974A2CD99

Q35056738-F9B0579C-8001-457C-A369-2369A070CEEC

P2860

Q35056738-008B522D-7218-4E94-BD01-EE3DF3F9745C

Q35056738-020BDAA3-7A68-4ECC-B83B-764ED5904D49

Q35056738-034972EE-D310-4348-AAB3-63DCD859F1CE

Q35056738-0478C881-DFF8-4ACD-85A2-0BE5DDEB2851

Q35056738-0877D0E8-2B2A-48C0-A4B1-EFFAC608B3E3

Q35056738-0B151379-ED15-401C-9F48-F4BE16BF16D7

Q35056738-0B4132F3-CBC5-4A48-9987-76489B437738

Q35056738-0D6D2EEC-4A30-4C6B-9840-92AEAE10E4A0

Q35056738-126BCC40-1739-4FC8-80A1-A7FDB807C665

Q35056738-1663D8EB-05A8-45EB-8380-93B650625A1D

P304

Q35056738-A31B3CA1-98FA-4F48-A0AE-18F4B9C14394

P31

Q35056738-40f0b328-da95-4465-824f-4f6cd89b5fcc

Q35056738-65E49478-B92D-479A-9767-33238234F64D

P356

Q35056738-43306E1D-C778-48E7-AF36-5E4BB3F9C676

P433

Q35056738-4639AB3C-E368-499A-8F82-71DFF819EF5F

P478

Q35056738-376B5260-9E32-436C-ACC0-6BCC853ED969

P577

Q35056738-5CE7709B-9AD3-4D99-9CEF-69C2BBBC3D71

P5875

Q35056738-442CF3A7-8FDB-4307-827F-FB201A74BD27

P698

Q35056738-66B573CA-6148-479E-A4DD-9C681F349F7C

P932

Q35056738-7D4CB0CC-231B-4B42-B203-C9C1986FCA02

P356

187152010794473957

P1433

Anti-Cancer Agents in Medicinal Chemistry

P1476

ABC transporters: unvalidated therapeutic targets in cancer and the CNS

@en

P2093

Laleh Amiri-Kordestani

http://www.w3.org/2001/XMLSchema#string

Paul R Massey

http://www.w3.org/2001/XMLSchema#string

Robert W Robey

http://www.w3.org/2001/XMLSchema#string

Susan E Bates

http://www.w3.org/2001/XMLSchema#string

P2860

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

Multidrug resistance in cancer: role of ATP-dependent transporters

A "silent" polymorphism in the MDR1 gene changes substrate specificity

A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Doxorubicin gradients in human breast cancer.

ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra?

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier.

P304

625-633

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/187152010794473957

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49712531

http://www.w3.org/2001/XMLSchema#string

P698

21189132

http://www.w3.org/2001/XMLSchema#string

P932

3119022

http://www.w3.org/2001/XMLSchema#string